Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study - PubMed (original) (raw)
Comparative Study
Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study
A Solomon et al. Neurology. 2007.
Abstract
Background: Longitudinal studies have shown that high serum total cholesterol (TC) at midlife is a risk factor for dementia/Alzheimer disease. The significance of TC later in life is unclear.
Objective: To investigate changes in serum TC from midlife to late life and their relationship with late-life cognition.
Methods: Participants of the Cardiovascular Risk Factors, Aging and Dementia study were derived from random, population-based samples previously studied in a survey in 1972, 1977, 1982, or 1987. After an average follow-up of 21 years, 1,449 individuals aged 65 to 79 were reexamined in 1998.
Results: Serum TC levels decreased in most individuals. High midlife TC represented a risk factor for more severe cognitive impairment later in life, and the values were significantly different between the control, mild cognitive impairment, and dementia groups. There were no significant differences in serum TC at reexamination. A moderate decrease in serum TC from midlife to late life (0.5 to 2 mmol/L) was significantly associated with the risk of a more impaired late-life cognitive status, even after adjusting for age, follow-up time, sex, years of formal education, midlife cholesterol, changes in body mass index, APOE epsilon4 genotype, history of myocardial infarction/stroke/diabetes, and lipid-lowering treatment.
Conclusions: The relationship between serum total cholesterol (TC) and dementia seems to be bidirectional. High midlife serum TC is a risk factor for subsequent dementia/Alzheimer disease, but decreasing serum TC after midlife may reflect ongoing disease processes and may represent a risk marker for late-life cognitive impairment.
Similar articles
- Serum total cholesterol, statins and cognition in non-demented elderly.
Solomon A, Kåreholt I, Ngandu T, Wolozin B, Macdonald SW, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M. Solomon A, et al. Neurobiol Aging. 2009 Jun;30(6):1006-9. doi: 10.1016/j.neurobiolaging.2007.09.012. Epub 2007 Nov 19. Neurobiol Aging. 2009. PMID: 18022292 Clinical Trial. - Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease.
Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A. Kivipelto M, et al. Arch Neurol. 2005 Oct;62(10):1556-60. doi: 10.1001/archneur.62.10.1556. Arch Neurol. 2005. PMID: 16216938 - Lipid metabolism in cognitive decline and dementia.
Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, Capurso A, Solfrizzi V. Panza F, et al. Brain Res Rev. 2006 Aug;51(2):275-92. doi: 10.1016/j.brainresrev.2005.11.007. Epub 2006 Jan 10. Brain Res Rev. 2006. PMID: 16410024 Review. - Serum cholesterol and risk of Alzheimer disease: a community-based cohort study.
Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB. Li G, et al. Neurology. 2005 Oct 11;65(7):1045-50. doi: 10.1212/01.wnl.0000178989.87072.11. Neurology. 2005. PMID: 16217057 - The epidemiologic study of dementia: a life-long quest?
Launer LJ. Launer LJ. Neurobiol Aging. 2005 Mar;26(3):335-40. doi: 10.1016/j.neurobiolaging.2004.03.016. Neurobiol Aging. 2005. PMID: 15639311 Review.
Cited by
- Synthesis, biological and computational evaluation of benzoxazole hybrid analogs as potential anti-Alzheimer's agents.
Othman MS, Hussain R, Rahim F, Ullah H, Khan S, Taha M, Fareid MA, Altaleb AT, Aboelnaga SM, Shah SAA. Othman MS, et al. Future Med Chem. 2024;16(19):2013-2023. doi: 10.1080/17568919.2024.2393569. Epub 2024 Sep 13. Future Med Chem. 2024. PMID: 39269160 - Epilepsy, Vascular Risk Factors, and Cognitive Decline in Older Adults: The Cardiovascular Health Study.
Choi H, Elkind MSV, Longstreth WT Jr, Boehme AK, Hafen R, Hoyt EJ, Thacker EL. Choi H, et al. Neurology. 2022 Nov 22;99(21):e2346-e2358. doi: 10.1212/WNL.0000000000201187. Epub 2022 Sep 2. Neurology. 2022. PMID: 36240101 Free PMC article. - Vascular dementia: a review of recent evidence for prevention and treatment.
Kirshner HS. Kirshner HS. Curr Neurol Neurosci Rep. 2009 Nov;9(6):437-42. doi: 10.1007/s11910-009-0065-y. Curr Neurol Neurosci Rep. 2009. PMID: 19818230 Review. - Higher incidence of mild cognitive impairment in familial hypercholesterolemia.
Zambón D, Quintana M, Mata P, Alonso R, Benavent J, Cruz-Sánchez F, Gich J, Pocoví M, Civeira F, Capurro S, Bachman D, Sambamurti K, Nicholas J, Pappolla MA. Zambón D, et al. Am J Med. 2010 Mar;123(3):267-74. doi: 10.1016/j.amjmed.2009.08.015. Am J Med. 2010. PMID: 20193836 Free PMC article. - The relationship between blood lipids and plasma amyloid beta is depend on blood pressure: a population-based cross-sectional study.
Hu N, Gao L, Jiang Y, Wei S, Shang S, Chen C, Dang L, Wang J, Huo K, Deng M, Wang J, Qu Q. Hu N, et al. Lipids Health Dis. 2020 Jan 14;19(1):8. doi: 10.1186/s12944-020-1191-4. Lipids Health Dis. 2020. PMID: 31937307 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous